The abstract is read at the publisher; the summary is JClub's.
STRAD-binding small molecules activate the tumor suppressor kinase LKB1, reducing viability in cancer cell lines by augmenting LKB1 signaling through the obligate MO25–STRAD–LKB1 trimer.
- Why it matters: Targeted cancer therapies usually inhibit oncogenic proteins, but boosting tumor-suppressive signaling is harder because kinase activators and allosteric pockets are less defined.
- What they did: The work designs compounds that bind STRAD’s ATP-binding pocket (STRAD binds but does not metabolize ATP) to allosterically activate LKB1 within the MO25–STRAD–LKB1 complex.
- The result: In cancer cell lines, STRAD-binding compounds activate LKB1 to augment tumor-suppressive signaling and reduce cell viability, supporting an allosteric activation strategy for tumors with intact LKB1.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.